EE200300342A - Imidasolüüli derivaadid kui kortikotropiini vabastava faktori inhibiitorid, nende saamismeetodid ning kasutamine - Google Patents

Imidasolüüli derivaadid kui kortikotropiini vabastava faktori inhibiitorid, nende saamismeetodid ning kasutamine

Info

Publication number
EE200300342A
EE200300342A EEP200300342A EEP200300342A EE200300342A EE 200300342 A EE200300342 A EE 200300342A EE P200300342 A EEP200300342 A EE P200300342A EE P200300342 A EEP200300342 A EE P200300342A EE 200300342 A EE200300342 A EE 200300342A
Authority
EE
Estonia
Prior art keywords
inhibitors
preparation
methods
releasing factor
corticotropin releasing
Prior art date
Application number
EEP200300342A
Other languages
English (en)
Estonian (et)
Inventor
M. Dubowchik Gene
Han Xiaojun
M. Vrudhula Vivekananda
Zuev Dmitry
Dasgupta Bireshwar
A. Michne Jodi
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of EE200300342A publication Critical patent/EE200300342A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
EEP200300342A 2001-01-26 2002-01-11 Imidasolüüli derivaadid kui kortikotropiini vabastava faktori inhibiitorid, nende saamismeetodid ning kasutamine EE200300342A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26457001P 2001-01-26 2001-01-26
PCT/US2002/000841 WO2002058704A1 (en) 2001-01-26 2002-01-11 Imidazolyl derivatives as corticotropin releasing factor inhibitors

Publications (1)

Publication Number Publication Date
EE200300342A true EE200300342A (et) 2003-12-15

Family

ID=23006646

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300342A EE200300342A (et) 2001-01-26 2002-01-11 Imidasolüüli derivaadid kui kortikotropiini vabastava faktori inhibiitorid, nende saamismeetodid ning kasutamine

Country Status (22)

Country Link
US (5) US6888004B2 (cs)
EP (1) EP1359916A4 (cs)
JP (1) JP2004531475A (cs)
KR (1) KR20040034594A (cs)
CN (1) CN1499972A (cs)
BG (1) BG107999A (cs)
BR (1) BR0206698A (cs)
CA (1) CA2434558A1 (cs)
CZ (1) CZ20032044A3 (cs)
EE (1) EE200300342A (cs)
HR (1) HRP20030675A2 (cs)
HU (1) HUP0303721A2 (cs)
IL (1) IL156813A0 (cs)
IS (1) IS6889A (cs)
MX (1) MXPA03006484A (cs)
NO (1) NO20033350L (cs)
PE (1) PE20020844A1 (cs)
PL (1) PL368555A1 (cs)
RU (1) RU2003126188A (cs)
SK (1) SK9222003A3 (cs)
WO (1) WO2002058704A1 (cs)
ZA (1) ZA200305531B (cs)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200300342A (et) * 2001-01-26 2003-12-15 Bristol-Myers Squibb Company Imidasolüüli derivaadid kui kortikotropiini vabastava faktori inhibiitorid, nende saamismeetodid ning kasutamine
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
US7091215B2 (en) 2001-04-27 2006-08-15 Eisai Co., Ltd. Pyrazolo[1,5-a]pyridines and medicines containing the same
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
WO2004037822A1 (ja) 2002-10-22 2004-05-06 Eisai Co., Ltd. ７−フェニルピラゾロピリジン化合物
WO2006065793A2 (en) * 2004-12-13 2006-06-22 Indevus Pharmaceuticals, Inc. TREATMENT OF INTERSTITIAL CYSTITIS USING (6aR,10aR)-Δ8-TETRAHYDROCANNABINOL-11-OIC ACIDS
US7815905B2 (en) * 2006-01-27 2010-10-19 Research Development Foundation Methods of increasing insulin sensitivity or decreasing insulin secretion by administering corticotropin releasing factor receptor-2 inhibitors
EP2167094A2 (en) 2007-06-13 2010-03-31 Research Development Foundation Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling
EA017688B1 (ru) * 2007-11-29 2013-02-28 Бёрингер Ингельхайм Интернациональ Гмбх ПРОИЗВОДНЫЕ АМИДОВ 6,7-ДИГИДРО-5Н-ИМИДАЗО[1,2-a]ИМИДАЗОЛ-3-КАРБОНОВОЙ КИСЛОТЫ
CN102007133B (zh) 2008-04-15 2013-06-12 卫材R&D管理有限公司 3-苯基吡唑并[5,1-b]噻唑化合物
US7994203B2 (en) * 2008-08-06 2011-08-09 Novartis Ag Organic compounds
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
US20120295942A1 (en) * 2010-02-01 2012-11-22 Nicholas James Devereux Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists
US9806270B2 (en) 2011-03-25 2017-10-31 Udc Ireland Limited 4H-imidazo[1,2-a]imidazoles for electronic applications
KR102116313B1 (ko) * 2011-03-25 2020-06-01 유디씨 아일랜드 리미티드 전자장치 응용을 위한 4h-이미다조[1,2-a]이미다졸
CN108299439B (zh) 2011-11-10 2021-02-09 Udc 爱尔兰有限责任公司 用于电子应用的4H-咪唑并[1,2-a]咪唑
WO2013117601A1 (de) 2012-02-07 2013-08-15 Bayer Intellectual Property Gmbh Verfahren zur herstellung von substituierten anthranilsäure-derivaten
IN2014DN10229A (cs) 2012-05-25 2015-08-07 Nutech Ventures
EP2872512B1 (en) 2012-07-10 2017-05-10 UDC Ireland Limited Benzimidazo[1,2-a]benzimidazole derivatives for electronic applications
BR112015001201B1 (pt) * 2012-07-18 2022-02-22 University Of Notre Dame Du Lac Compostos anti-infecciosos 5,5-heteroaromáticos e composição
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
CN105384691B (zh) * 2015-10-26 2018-06-29 深圳大学 一种谷氨酰胺酰基环化酶抑制剂的制备方法及应用
CA3069736A1 (en) * 2017-07-24 2019-01-31 University Of South Florida Novel bis-cyclic guanidines as antibacterial agents
US10729693B2 (en) * 2018-03-02 2020-08-04 Ponce Medical School Foundation, Inc. Compositions and methods for the treatment of endometriosis

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865836A (en) * 1972-12-08 1975-02-11 Janssen Pharmaceutica Nv Bicyclic imidazoles
DE2827617A1 (de) * 1978-06-23 1980-01-10 Boehringer Sohn Ingelheim Neue imidazo eckige klammer auf 1,2- alpha eckige klammer zu imidazole, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu deren herstellung
IL69417A (en) * 1982-08-27 1987-12-20 Roussel Uclaf 2-acyl imidazo(1,2-a)pyrimidines,their preparation and pharmaceutical compositions containing them
US4551530A (en) * 1984-11-19 1985-11-05 American Cyanamid Company Pyridyl imidazo[1,2-a]pyrimidines
DK155524C (da) * 1987-03-18 1989-09-11 Ferrosan As Kondenserede imidazolderivater og farmaceutiske praeparater indeholdende disse
JPH05107705A (ja) * 1991-10-17 1993-04-30 Konica Corp 新規な写真用カプラー
DE69321875T2 (de) * 1992-05-19 1999-06-17 Adir Et Compagnie, Courbevoie Benzimidezolderivate mit antidiabetischer und Anti-Plättchenklumpungswirkung
EP0607076A1 (fr) * 1993-01-15 1994-07-20 Synthelabo Dérivés de 9h-imidazo 1,2-a benzimidazole-3-acétamide à activité GABA
FR2722501B1 (fr) * 1994-07-13 1996-08-09 Synthelabo Derives de 9h-imidazo(1,2-a)benzimidazole-3-acetamide, leur preparation et leur application en therapeutique
PT778277E (pt) 1995-12-08 2003-11-28 Pfizer Derivados heterociclicos substituidos como antagonistas do crf
TR199800792T2 (xx) * 1996-02-07 1998-07-21 Janssen Pharmaceutica N.V. CRF resept�r antagonistleri olarak pirazolopirimidinler.
US6022978A (en) 1996-06-11 2000-02-08 Pfizer Inc. Benzimidazole derivatives
WO1998014452A1 (fr) * 1996-10-03 1998-04-09 Nissan Chemical Industries, Ltd. Derives de pyrimidinone a heterocycle fusionne et herbicides
AU6279598A (en) 1997-02-18 1998-09-08 Neurocrine Biosciences, Inc. Biazacyclic CRF antagonists
CN1268137A (zh) 1997-07-03 2000-09-27 杜邦药品公司 治疗神经失调的咪唑并嘧啶和咪唑并吡啶
AU9021598A (en) 1997-08-22 1999-03-16 Du Pont Pharmaceuticals Company Nitrogen substituted imidazo{4,5-c}pyrazoles as corticotropin relea sing hormone antagonists
BR9803368A (pt) 1997-09-05 2001-04-24 Sumitomo Chemical Co Derivados de perimidona e herbecidas contendo os mesmos
WO1999024038A1 (en) * 1997-11-07 1999-05-20 Johns Hopkins University Methods for treatment of disorders of cardiac contractility
AU1687199A (en) * 1997-12-26 1999-07-19 Takeda Chemical Industries Ltd. Nitrogen-containing heterocyclic compounds, their production and use
US6509338B1 (en) 1998-06-22 2003-01-21 Bristol-Myers Squibb Company Pyrazolo[1,5-A]triazine corticotropin releasing factor antagonists
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US6124463A (en) 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
US6271380B1 (en) 1998-12-30 2001-08-07 Dupont Pharmaceuticals Company 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
AU4203500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
AU4331500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolotriazines as crf antagonists
US6492408B1 (en) * 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
CA2416906A1 (en) * 2000-08-09 2002-02-14 Boehringer Ingelheim Pharmaceuticals, Inc. Synthesis of (r)-3-(4-bromobenzyl)-1-(3,5-dichlorophenyl)-5-iodo-3-methyl-1-h-imidazo[1,2-a]imidazol-2-one
US6696441B1 (en) * 2000-08-11 2004-02-24 The Regents Of The University Of California Inhibition of p53-induced stress response
US6515005B2 (en) * 2000-09-21 2003-02-04 Bristol-Myers Squibb Company Substituted azole derivatives as inhibitors of corticotropin releasing factor
EE200300342A (et) * 2001-01-26 2003-12-15 Bristol-Myers Squibb Company Imidasolüüli derivaadid kui kortikotropiini vabastava faktori inhibiitorid, nende saamismeetodid ning kasutamine

Also Published As

Publication number Publication date
US7125990B2 (en) 2006-10-24
BR0206698A (pt) 2004-04-20
US20040254382A1 (en) 2004-12-16
HUP0303721A2 (hu) 2004-03-01
US20040225130A1 (en) 2004-11-11
ZA200305531B (en) 2004-07-27
PE20020844A1 (es) 2002-09-27
IL156813A0 (en) 2004-02-08
US7211669B2 (en) 2007-05-01
NO20033350L (no) 2003-09-22
CA2434558A1 (en) 2002-08-01
WO2002058704A1 (en) 2002-08-01
JP2004531475A (ja) 2004-10-14
KR20040034594A (ko) 2004-04-28
US7238699B2 (en) 2007-07-03
EP1359916A1 (en) 2003-11-12
BG107999A (en) 2004-08-31
CZ20032044A3 (cs) 2003-12-17
US20020183375A1 (en) 2002-12-05
NO20033350D0 (no) 2003-07-25
SK9222003A3 (en) 2004-05-04
RU2003126188A (ru) 2005-03-27
US20040235924A1 (en) 2004-11-25
US7244746B2 (en) 2007-07-17
MXPA03006484A (es) 2003-09-22
US6888004B2 (en) 2005-05-03
IS6889A (is) 2003-07-24
PL368555A1 (en) 2005-04-04
EP1359916A4 (en) 2004-04-07
CN1499972A (zh) 2004-05-26
US20040225001A1 (en) 2004-11-11
HRP20030675A2 (en) 2004-08-31

Similar Documents

Publication Publication Date Title
EE200300342A (et) Imidasolüüli derivaadid kui kortikotropiini vabastava faktori inhibiitorid, nende saamismeetodid ning kasutamine
EE05387B1 (et) KinasoliiniÁderivaadid,ÁnendeÁvalmistamismeetodÁjaÁkasutamine
PL367272A1 (en) Novel substituted benzimidazole dosage forms and method of using same
EE200200118A (et) Terapeutilised kinasoliini derivaadid, nende valmistamise meetod ning kasutamine
EE200500011A (et) Indasoolid, bensotiasoolid ja bensoisotiasoolid, nende valmistamine ning kasutamine
SI1499589T1 (sl) Derivati N-(fenil(piperidin-2-il)metil)benzamida,njihova priprava in njihova terapevtska uporaba
PL374832A1 (en) Novel substituted benzimidazole dosage forms and method of using same
IS6656A (is) Útskiptar kínasólínafleiður og notkun þeirra sem hemla
EE200300151A (et) Ravimitena kasutatavad antikolinergikumid ning meetodid nende valmistamiseks
ZA200603937B (en) Derivatives of N-phenyl (piperidine-2-yl) methyl benzamide, preparation method thereof and applications of same in therapeutics
SI2305250T1 (sl) Benzimidazolni derivati in njih uporabo kot inhibitorji protein-kinaz
EE200300544A (et) 4-anilinokinoliin-3-karboksamiidid, nende kasutamine ning valmistamine
MXPA03006010A (es) Derivados de arilamina sustituida y metodos de uso.
IL161258A0 (en) Heterocyclic compounds and methods of use
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
IS8422A (is) Bensímídasólafleiður, efnablöndur sem innihalda þær, framleiðsla þeirra og notkun þeirra
NO20040726L (no) Kombinasjonspreparater av arylsubstituerte propanolaminderivater med andre aktive forbindelser og anvendelse derav.
DK1537096T3 (da) Derivater af dioxan-2-alkylcarbamater, fremstilling og terapeutisk anvendelse heraf
EE200400043A (et) Uudsed heterotsüklilised ühendid kui selektiivsedbakteriaalsed DHFR inhibiitorid ning nende kasutamine
NO20042244L (no) Fenylsubstituerte triazoler og deres anvendelse som selektive inhibitorer av AKL5-kinease
PL370657A1 (en) Quinazolinone derivatives and their use as cb agonists
IS8219A (is) Bensímídasólafleiður, efnablöndur sem innihalda þær, framleiðsla þeirra og notkun
AU9625501A (en) Substituted azole derivatives as inhibitors of corticotropin releasing factor
IS2773B (is) Amínókínólínafleiður og notkun þeirra sem adenósín A3-bindlar
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof